- Home
- MNPR vs FHTX Comparison
MNPR vs FHTX Comparison
Compare MNPR & FHTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | MNPR | FHTX |
|---|---|---|
| Founded | 2014 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Medicinal Chemicals and Botanical Products |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 368.9M | 323.4M |
| IPO Year | 2019 | 2020 |
Fundamental Metrics
Financial Performance| Metric | MNPR | FHTX |
|---|---|---|
| Price | $58.91 | $3.84 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 11 | 8 |
| Target Price | ★ $107.00 | $11.50 |
| AVG Volume (30 Days) | ★ 160.0K | 102.8K |
| Earning Date | 05-08-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 54.99 | 25.32 |
| EPS | N/A | ★ N/A |
| Revenue | N/A | ★ $30,909,000.00 |
| Revenue This Year | N/A | $8.89 |
| Revenue Next Year | N/A | $20.13 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ 36.75 |
| 52 Week Low | $28.40 | $3.27 |
| 52 Week High | $105.00 | $6.95 |
Technical Indicators
Market Signals| Indicator | MNPR | FHTX |
|---|---|---|
| Relative Strength Index (RSI) | 52.54 | 29.09 |
| Support Level | $50.60 | $3.65 |
| Resistance Level | $61.51 | $5.82 |
| Average True Range (ATR) | 4.38 | 0.27 |
| MACD | 0.47 | -0.09 |
| Stochastic Oscillator | 51.18 | 2.68 |
Price Performance
Historical ComparisonAbout MNPR Monopar Therapeutics Inc.
Monopar Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing proprietary therapeutics designed to extend life or improve the quality of life for cancer patients. The company's pipeline consists of Validive for the prevention of chemoradiotherapy-induced severe oral mucositis in oropharyngeal cancer patients, camsirubicinfor the treatmentof soft tissue sarcoma, a late-stage preclinical antibody, MNPR-101, for cancers and severe COVID-19 and an early-stage camsirubicin analog, MNPR-202, for various cancers.
About FHTX Foghorn Therapeutics Inc.
Foghorn Therapeutics Inc is a clinical stage, precision therapeutics biotechnology company focused on pioneering a new class of medicines that treat serious diseases by correcting abnormal gene expression through selectively targeting the chromatin regulatory system. Its proprietary platform is designed to provide an integrated, mechanistic understanding of interactions within the chromatin regulatory system, supporting the identification and validation of potential therapeutic targets. The company's flagship program is FHD-909.